Andean Precious Metals (CVE:APM) Price Target Lowered to C$2.00 at Desjardins

Andean Precious Metals (CVE:APM) had its price target lowered by investment analysts at Desjardins from C$2.10 to C$2.00 in a research report issued on Thursday,BayStreet.CA reports. The brokerage presently has a “buy” rating on the stock. Desjardins’ price objective suggests a potential upside of 55.04% from the stock’s current price.

Andean Precious Metals Stock Performance

APM stock traded up C$0.09 during midday trading on Thursday, reaching C$1.29. 225,691 shares of the company were exchanged, compared to its average volume of 159,585. Andean Precious Metals has a 1-year low of C$0.57 and a 1-year high of C$2.18. The stock’s 50-day simple moving average is C$1.29 and its 200 day simple moving average is C$1.36. The company has a market cap of C$135.47 million, a price-to-earnings ratio of 2.55 and a beta of 1.22.

Insiders Place Their Bets

In other news, Senior Officer Juan Carlos Sandoval Amare acquired 31,300 shares of the stock in a transaction that occurred on Friday, January 3rd. The shares were purchased at an average cost of C$1.21 per share, for a total transaction of C$37,860.48. 69.37% of the stock is owned by corporate insiders.

Andean Precious Metals Company Profile

Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases.